Sunifiram (DM-235)

Sunifiram (DM-235)

Sunifiram (DM-235)

Sunifiram (DM-235)

Sunifiram (DM-235 / 1-(4-benzoylpiperazin-1-yl)propan-1-one) is an achiral benzoylpiperazine designed by simplifying unifiram, for glutamatergic signalling and structure-activity research. In hippocampal slice recordings it enhanced NMDA receptor-dependent LTP through the glycine site and PKCα, Src and CaMKII signalling, with no confirmed direct binding site. CAS 314728-85-3.

Original price was: $64.00.Current price is: $44.80.

In stock

Original price was: $64.00.Current price is: $44.80.
Bundle & save
Quantity Discounted Price
3 - 5 $61.44
6 - 9 $58.88
10 + $57.60
Order now · ships Monday
We ship Mon–Fri · cutoff 5:00 PM EST
Arrives Wed, Nov 25 – Fri, Nov 27
Free shipping on orders over $200
Premium shipping insurance available
Add it at cart/checkout
Priority Overnight shipping available
Pick your speed at checkout

What is Sunifiram (DM-235)?

Sunifiram (1-(4-benzoylpiperazin-1-yl)propan-1-one, also called DM-235 or DM235; CAS 314728-85-3) is a small, achiral benzoylpiperazine: a piperazine ring carrying a benzoyl group on one nitrogen and a propionyl group on the other. It was designed by molecular simplification of unifiram (DM-232), a bicyclic lactam, and the N-acylpiperazine was found to stand in for the 2-pyrrolidinone ring of that series (Manetti et al., 2000, PubMed 11087574). Sunifiram is not a racetam and not a peptide, and no direct binding site has been confirmed for it.

In hippocampal slice recordings, sunifiram enhanced NMDA receptor-dependent long-term potentiation (LTP) at 10 to 100 nM, with a bell-shaped curve that peaked at 10 nM. The effect depended on the NMDA receptor glycine-binding site and ran through PKCα, Src and CaMKII signalling (Moriguchi et al., 2013, PubMed 23733502). AMPA receptor effects appear downstream of that signalling rather than as a demonstrated binding event.

At Modern Aminos, Sunifiram is supplied in one laboratory format:

  • Liquid (solution), with the concentration and fill volume printed on the bottle label

Laboratories building glutamatergic signalling and structure-activity panels often read sunifiram next to its parent compound, unifiram. For the mechanism evidence in depth, see Sunifiram Mechanism of Action: DM-235 Specs, Structure and Lab Data.

Chemical and Molecular Data for Sunifiram (DM-235)

Compound Name Sunifiram (DM-235)
Research Category N-acylpiperazine (benzoylpiperazine) diamide; glutamatergic signalling and SAR reference compound
Quantity / Formats Offered Liquid (solution); concentration and fill volume as printed on the label
Synonyms / Alt Names DM-235; DM235; DM 235; 1-benzoyl-4-(1-oxopropyl)piperazine
CAS Number 314728-85-3
PubChem CID 4223812
FDA UNII 66924E735K
Chemical Formula C14H18N2O2
Molecular Weight 246.30 g/mol
Exact Mass 246.1368 Da
IUPAC Name 1-(4-benzoylpiperazin-1-yl)propan-1-one
InChIKey DGOWDUFJCINDGI-UHFFFAOYSA-N
SMILES Code CCC(=O)N1CCN(CC1)C(=O)C2=CC=CC=C2

Identity fields are drawn from PubChem CID 4223812; the current certificate is in the Certificate of Analysis tab.

What are the Mechanisms of Action?

The biochemical targets and pathway logic of Sunifiram in laboratory research include:

  • No confirmed binding site: In binding studies, sunifiram showed no affinity for the main central receptors or ion channels, so its direct molecular target remains unknown (Romanelli et al., 2006).
  • NMDA receptor glycine site dependence: 7-chlorokynurenic acid, a glycine-site NMDA antagonist, blocked sunifiram’s LTP enhancement, while ifenprodil did not; saturating the glycine site with 300 µM glycine also removed the effect (Moriguchi et al., 2013).
  • PKCα and Src kinase relay: Without an LTP-inducing stimulus, sunifiram raised PKCα (Ser-657) and Src family (Tyr-416) phosphorylation with the same bell-shaped curve, and the Src inhibitor PP2 reduced the LTP enhancement (Moriguchi et al., 2013).
  • CaMKII and downstream AMPA receptor phosphorylation: Enhanced LTP came with more CaMKII activity and more phosphorylation of AMPA receptor subunits. In an earlier slice release assay, the AMPA antagonist NBQX abolished sunifiram’s effect, which places AMPA receptors in the pathway without showing direct binding (Galeotti et al., 2003).

What Does Published Research Show for Sunifiram?

Peer-reviewed literature on Sunifiram (DM-235) centers on scaffold design, structure-activity relationships and slice electrophysiology:

  • Scaffold design (PubMed): Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones produced N-acylpiperazines such as DM-235 (PubMed 11087574).
  • Structure-activity relationships (PubMed): A follow-up SAR study varied both acyl groups and the ring, and none of the new analogs matched the potency of unifiram and sunifiram (PubMed 14697772).
  • Glycine-site mechanism (PubMed): Hippocampal slice recordings linked sunifiram’s LTP enhancement to the NMDA receptor glycine site and PKCα, Src and CaMKII signalling (PubMed 23733502).
  • Series review (PMC): A pharmacological review of DM-232 and DM-235 reported no affinity at the main central receptors or channels in binding screens (PMC6741768).
  • Chemical Directory & Structure Verification (PubChem): CAS 314728-85-3, C14H18N2O2, 246.30 g/mol and InChIKey DGOWDUFJCINDGI-UHFFFAOYSA-N (PubChem CID 4223812).
  • Analytical Quality: Why chromatographic testing matters for reference materials is covered in Modern Aminos’ note on HPLC testing.

How does Sunifiram compare to other compounds?

To map scaffold changes against activity, researchers compare Sunifiram with its parent compound, unifiram, and with piracetam, the benchmark the original series used. Reference listings are available at Modern Aminos:

Compound / Reference Structure and Identity Core Mechanism Evidence Research Focus & Profile
Sunifiram (DM-235) Monocyclic, achiral benzoylpiperazine diamide; C14H18N2O2, 246.30 g/mol; CAS 314728-85-3 No confirmed binding site; LTP enhancement dependent on the NMDA glycine site, PKCα, Src and CaMKII Simplified scaffold for SAR and glutamatergic signalling work
Unifiram (DM-232) Bicyclic lactam fused to a piperazine-type ring with a 4-fluorobenzenesulfonyl group; one stereocenter; C13H15FN2O3S, 298.34 g/mol; CAS 272786-64-8 No confirmed binding site; AMPA receptor involvement shown functionally in slice release assays Parent scaffold of the series and enantiomer studies
Piracetam Monocyclic 2-pyrrolidinone with a primary acetamide; C6H10N2O2, 142.16 g/mol; CAS 7491-74-9 Benchmark compound for the series Reference point for racetam-type comparisons

In short, sunifiram keeps unifiram’s two-nitrogen layout but opens the fused ring into a plain piperazine, swaps the 4-fluorobenzenesulfonyl group for a benzoyl group and loses the stereocenter. For the parent compound in detail, see What Is Unifiram (DM-232)?

Frequently Asked Questions (FAQs)

1. Is Modern Aminos a reliable place to buy Sunifiram (DM-235)?

Modern Aminos posts a third-party Vanguard Laboratory certificate for the sunifiram raw material in the Certificate of Analysis tab. If you want to buy 1-(4-benzoylpiperazin-1-yl)propan-1-one as a documented reference material, compare any certificate you review against CAS 314728-85-3 and PubChem CID 4223812.

2. Is Sunifiram (DM-235) classed as a racetam?

Not structurally. Sunifiram has no 2-pyrrolidinone ring; it is an N-acylpiperazine. It is often grouped with racetams because its design series used piracetam as the reference compound.

3. What is the molecular target of sunifiram?

No direct target has been confirmed. Binding screens found no affinity at the main central receptors or channels, while slice recordings tie its activity to the NMDA receptor glycine site and PKCα, Src and CaMKII signalling.

4. Has direct AMPA receptor binding been shown for Sunifiram (DM-235)?

No direct binding has been shown. AMPA receptor involvement comes from functional work, where the AMPA antagonist NBQX abolished sunifiram’s effect in a slice release assay, and from increased AMPA receptor phosphorylation downstream of CaMKII.

5. How does the NMDA glycine site relate to sunifiram’s effect on LTP?

In hippocampal slice recordings, the glycine-site antagonist 7-chlorokynurenic acid blocked sunifiram’s LTP enhancement, and saturating the site with glycine removed it. Sunifiram’s peak effect was at 10 nM.

6. How is sunifiram different from unifiram?

Unifiram (DM-232) is a chiral bicyclic lactam with a 4-fluorobenzenesulfonyl group, C13H15FN2O3S at 298.34 g/mol. Sunifiram (DM-235) is its simplified, achiral piperazine analog, C14H18N2O2 at 246.30 g/mol. For more, see What Is Unifiram (DM-232)?

7. Which identifiers confirm sunifiram?

Match CAS 314728-85-3, PubChem CID 4223812 or InChIKey DGOWDUFJCINDGI-UHFFFAOYSA-N. The formula C14H18N2O2 also separates it from unifiram, which contains fluorine and sulfur.

8. What available formats does Modern Aminos offer for Sunifiram research?

Modern Aminos lists sunifiram in one liquid (solution) format. The concentration and fill volume are printed on the bottle label, and the certificate is in the Certificate of Analysis tab.

9. Where can I read more about the sunifiram mechanism of action?

The companion post Sunifiram Mechanism of Action: DM-235 Specs, Structure and Lab Data walks through the slice data, the naming traps and the full reference list.

10. What are the proper storage protocols for sunifiram?

Keep the bottle tightly sealed in a cool, dry place away from light. Follow the label on each lot.

DISCLAIMER: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research use only. They are not approved for human consumption by the Food and Drug Administration (FDA). No products are approved for oral, sublingual, nor in vivo use. These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.

0